The Future of cell & gene therapy manufacturing services is primarily driven by the high incidence of cancer and other target diseases, increasing investments in pharmaceutical R&D, investments in advanced technologies by CDMOs, and increasing partnerships & agreements between pharmaceutical companies and CDMOs.
According to GEP Worldwide, more than 1,200 clinical trials across the globe were disrupted by June 2020. Nearly 61% of clinical trials were disrupted due to the suspension of patient enrolment. The impact varied due to changes in COVID-19 case volumes throughout the year, but the worst effect was seen in April 2020.
The pandemic slowed the economic growth of various countries, including the US, Germany, the UK, India, and China. It also resulted in control measures that impacted operations in life science organizations, such as production and research.
The increase in pharmaceutical R&D has resulted in a sharp increase in the number of cell & gene therapy candidates under development. This has made it necessary to outsource manufacturing services to develop cost-effective and efficient cell & gene therapies.
Download PDF Copy of this Report to understand structure of the complete report (Including Full TOC, Table & Figures) @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=180609441
Currently, there are 1,200 cell & gene therapies in trials worldwide. There are more than 700 investigational cell & gene therapies in clinical development in the US alone. However, manufacturing facilities have not kept up. It has been estimated that hundreds of facilities will be needed to manufacture the treatments that are now in clinical trials.
The cost of manufacturing for gene therapy can be between USD 500,000 and USD 1 million, excluding the costs for R&D, the costs to run crucial clinical trials, or the costs to build the commercial infrastructure necessary to provide access to patients.
According to a 2020 PhRMA report on the cell & gene therapy pipeline in 2018, there were 289 cell & gene therapies in clinical development by biopharmaceutical companies. This number increased by 25% in 2020, with 362 cell & gene therapies in clinical development.
Global Cell & Gene Therapy Manufacturing Services Market Dynamics :-
1. DRIVER: Increasing investments in pharmaceutical R&D
2. RESTRAINT: High operational costs associated with cell & gene therapy manufacturing
3. OPPORTUNITY: Increasing number of cell & gene therapy clinical trials
On the basis of type, the cell & gene therapy manufacturing services market is broadly segmented into cell therapy and gene therapy. In 2020, cell therapy accounted for the largest share of the cell & gene therapy manufacturing services market.
The high growth rate in this segment can be attributed to the increasing expenditure on R&D by pharmaceutical & biotechnology companies, rising collaborations between pharmaceutical and biotechnology companies, and the growing number of cell & gene therapies in the R&D pipeline.
Primary and Secondary Research Methodology For Cell & Gene Therapy Manufacturing Services :-
In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify the critical qualitative and quantitative information as well as assess future prospects of the market.
Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the cell & gene therapy manufacturing services market. The secondary sources used for this study include Some of the key secondary sources referred to for this study include the American Society of Gene & Cell Therapy (ASGCT), Centers for Disease Control and Prevention (CDC), GLOBOCAN, World Health Organization (WHO).